Cystic fibrosis transmembrane conductance regulator

"CFTR" redirects here. For the Canadian radio station in Toronto, see CFTR (AM).

Cystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and anion channel in vertebrates that is encoded by the CFTR gene.^[5][6]

CFTR
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1XMI, 1XMJ, 2BBO, 2BBS, 2BBT, 2LOB, 2PZE, 2PZF, 2PZG, 3GD7, 3ISW, 4WZ6, 5D2D, 5D3E, 5D3F
Identifiers
Aliases	CFTR, ABC35, ABCC7, CF, CFTR/MRP, MRP7, TNR-dJ760C5.1, cystic fibrosis transmembrane conductance regulator, CF transmembrane conductance regulator
External IDs	OMIM: 602421; MGI: 88388; HomoloGene: 55465; GeneCards: CFTR; OMA:CFTR - orthologs
EC number	5.6.1.6
Gene location (Human) Chr. Chromosome 7 (human)[1] Band 7q31.2 Start 117,287,120 bp[1] End 117,715,971 bp[1]
Gene location (Mouse) Chr. Chromosome 6 (mouse)[2] Band 6 A2|6 8.1 cM Start 18,170,686 bp[2] End 18,322,767 bp[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in body of pancreas gallbladder rectum mucosa of sigmoid colon islet of Langerhans duodenum mucosa of transverse colon jejunal mucosa C1 segment minor salivary glands Top expressed in Paneth cell epithelium of small intestine Ileal epithelium duodenum left colon crypt of lieberkuhn of small intestine jejunum left lung lobe migratory enteric neural crest cell spermatid More reference expression data BioGPS n/a
Gene ontology Molecular function nucleotide binding PDZ domain binding chloride transmembrane transporter activity protein binding chloride channel inhibitor activity enzyme binding hydrolase activity ATP binding chloride channel activity ATPase-coupled inorganic anion transmembrane transporter activity chloride channel regulator activity ATPase-coupled transmembrane transporter activity intracellularly ATP-gated chloride channel activity ATPase activity bicarbonate transmembrane transporter activity chaperone binding Sec61 translocon complex binding isomerase activity Cellular component cytoplasm recycling endosome endosome early endosome membrane membrane plasma membrane chloride channel complex cell surface lysosomal membrane early endosome Golgi-associated vesicle membrane endoplasmic reticulum Sec complex extracellular exosome cytosol endosome membrane clathrin-coated vesicle membrane integral component of membrane apical plasma membrane endoplasmic reticulum endoplasmic reticulum membrane recycling endosome membrane integral component of plasma membrane nucleus protein-containing complex Biological process positive regulation of cyclic nucleotide-gated ion channel activity intracellular pH elevation membrane hyperpolarization positive regulation of voltage-gated chloride channel activity cholesterol transport ion transport vesicle docking involved in exocytosis transmembrane transport sperm capacitation positive regulation of insulin secretion involved in cellular response to glucose stimulus cholesterol biosynthetic process positive regulation of exocytosis chloride transport cellular response to cAMP protein deubiquitination membrane organization chloride transmembrane transport transepithelial water transport multicellular organismal water homeostasis cellular response to forskolin bicarbonate transport transport response to endoplasmic reticulum stress Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 1080 12638 Ensembl ENSG00000001626 ENSMUSG00000041301 UniProt P13569 P26361 RefSeq (mRNA) NM_000492 NM_021050 RefSeq (protein) NP_000483 NP_066388 Location (UCSC) Chr 7: 117.29 – 117.72 Mb Chr 6: 18.17 – 18.32 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Geneticist Lap-Chee Tsui and his team identified the CFTR gene in 1989 as the gene linked with CF (cystic fibrosis).^[7]

The CFTR gene codes for an ABC transporter-class ion channel protein that conducts chloride^[8] and bicarbonate ions across epithelial cell membranes. Mutations of the CFTR gene affecting anion channel function lead to dysregulation of epithelial lining fluid (mucus) transport in the lung, pancreas and other organs, resulting in cystic fibrosis. Complications include thickened mucus in the lungs with frequent respiratory infections, and pancreatic insufficiency giving rise to malnutrition and diabetes.^[9] These conditions lead to chronic disability and reduced life expectancy. In male patients, the progressive obstruction and destruction of the developing vas deferens (spermatic cord) and epididymis appear to result from abnormal intraluminal secretions,^[10] causing congenital absence of the vas deferens and male infertility, and found associated with an imbalance of fatty acids.^[11]

Tissue and intracellular localization

The CFTR is found in the epithelial cells of many organs including the lung, liver, pancreas, digestive tract, and the female reproductive tract^[12] and male reproductive tract including the testis, Sertoli cells, spermatozoa.^[13] epididymis,^[14] and the vas deferens.^[15]

In the airways of the lung, CFTR is most highly expressed by rare specialized cells called pulmonary ionocytes.^[16][17][18] In the skin, CFTR is strongly expressed in the sebaceous and eccrine sweat glands.^[19] In the eccrine glands, CFTR is located on the apical membrane of the epithelial cells that make up the duct of these sweat glands.^[19]

Normally, the protein allows movement of chloride, bicarbonate and thiocyanate^[20] ions (with a negative charge) out of an epithelial cell into the airway surface liquid and mucus. Positively charged sodium ions follow passively, increasing the total electrolyte concentration in the mucus, resulting in the movement of water out of the cell via osmosis.

In epithelial cells with motile cilia lining the bronchus and the oviduct, CFTR is located on the apical cell membrane but not on cilia.^[12] In contrast, ENaC (Epithelial sodium channel) is located along the entire length of the cilia.^[12]

In sweat glands, defective CFTR results in reduced transport of sodium chloride and sodium thiocyanate^[21] in the resorptive duct and therefore saltier sweat. This is the basis of a clinically important sweat test for cystic fibrosis often used diagnostically with genetic screening.^[22]

Gene

The location of the CFTR gene on chromosome 7

The gene that encodes the human CFTR protein is found on chromosome 7, on the long arm at position q31.2.^[6] from base pair 116,907,253 to base pair 117,095,955. CFTR orthologs^[23] occur in the jawed vertebrates.^{[24][failed verification]}

Each individual inherits two copies of the CFTR (cystic fibrosis transmembrane conductance regulator) gene. However, some of the inherited copies have been altered. So far, the CFTR gene has been associated with over 700 distinct mutations. An individual with CF inherits two defective copies of the CFTR gene. These mutations might be heterozygous, meaning they include two different mutations, and homozygous, meaning they involve the same mutation.^[25] Delta F508 is the most common mutation, accounting for more than 70% of all mutations. Those who are homozygous for Delta F508 are commonly affected by pancreatic insufficiency.^[26]

The CFTR gene has been used in animals as a nuclear DNA phylogenetic marker.^[23] Large genomic sequences of this gene have been used to explore the phylogeny of the major groups of mammals,^[27] and confirmed the grouping of placental orders into four major clades: Xenarthra, Afrotheria, Laurasiatheria, and Euarchonta plus Glires.

Mutations

Nearly 1000 cystic fibrosis-causing mutations have been described.^[28] The most common mutation, DeltaF508 (ΔF508) primarily known as a processing mutation which results from a deletion (Δ) of three nucleotides which results in a loss of the amino acid phenylalanine (F) at the 508th position on the protein.^[29] As a result, the protein does not fold normally and is more quickly degraded. The vast majority of mutations are infrequent. The distribution and frequency of mutations varies among different populations which has implications for genetic screening and counseling.

Drug discovery for therapeutics to address CF in all patients is complicated due to a large number of disease-causing mutations. Ideally, a library of cell lines and cell-based assays corresponding to all mutants is required to screen for broadly-active drug candidates. Cell engineering methods including fluorogenic oligonucleotide signaling probes may be used to detect and isolate clonal cell lines for each mutant.^[30]

Mutations consist of replacements, duplications, deletions or shortenings in the CFTR gene. This may result in proteins that may not function, work less effectively, are more quickly degraded, or are present in inadequate numbers.^[31]

It has been hypothesized that mutations in the CFTR gene may confer a selective advantage to heterozygous individuals. Cells expressing a mutant form of the CFTR protein are resistant to invasion by the Salmonella typhi bacterium, the agent of typhoid fever, and mice carrying a single copy of mutant CFTR are resistant to diarrhea caused by cholera toxin.^[32]

The most common mutations that cause cystic fibrosis and pancreatic insufficiency in humans are:^[33]

Variant cDNA name (ordered 5' to 3')	Variant protein name	Variant legacy name	rsID	# alleles in CFTR2	Allele frequency in CFTR2	% pancreatic insufficient	Variant final determination (July 2020)
c.1521_1523delCTT	p.Phe508del	F508del	rs113993960	99061	0.69744	98%	CF-causing
c.1624G>T	p.Gly542X	G542X	rs113993959	3610	0.02542	98%	CF-causing
c.1652G>A	p.Gly551Asp	G551D	rs75527207	2986	0.02102	96%	CF-causing
c.3909C>G	p.Asn1303Lys	N1303K	rs80034486	2246	0.01581	98%	CF-causing
c.350G>A	p.Arg117His	R117H	rs78655421	1854	0.01305	23%	Varying clinical consequence
c.3846G>A	p.Trp1282X	W1282X	rs77010898	1726	0.01215	99%	CF-causing
c.489+1G>T	No protein name	621+1G->T	rs78756941	1323	0.00931	99%	CF-causing
c.1657C>T	p.Arg553X	R553X	rs74597325	1323	0.00931	97%	CF-causing
c.1585-1G>A	No protein name	1717-1G->A	rs76713772	1216	0.00856	97%	CF-causing
c.3718-2477C>T	No protein name	3849+10kbC->T	rs75039782	1158	0.00815	33%	CF-causing
c.2657+5G>A	No protein name	2789+5G->A	rs80224560	1027	0.00723	43%	CF-causing
c.1519_1521delATC	p. Ile507del	I507del	rs121908745	651	0.00458	98%	CF-causing
c.3484C>T	p.Arg1162X	R1162X	rs74767530	651	0.00458	97%	CF-causing
c.254G>A	p.Gly85Glu	G85E	rs75961395	616	0.00434	85%	CF-causing
c.3454G>C	p.Asp1152His	D1152H	rs75541969	571	0.00402	24%	Varying clinical consequence
c.2051_2052delAAinsG	p. Lys684SerfsX38	2183AA->G	rs121908799	542	0.00382	96%	CF-causing
c.3528delC	p. Lys1177SerfsX15	3659delC	rs121908747	539	0.00379	99%	CF-causing
c.1040G>C	p.Arg347Pro	R347P	rs77932196	533	0.00375	68%	CF-causing
c.1210−12T[5]	No protein name	5T	rs1805177	516	0.00363	28%	Varying clinical consequence
c.2988+1G>A	No protein name	3120+1G->A	rs75096551	501	0.00353	98%	CF-causing
c.1364C>A	p.Ala455Glu	A455E	rs74551128	500	0.00352	34%	CF-causing
c.3140-26A>G	No protein name	3272-26A->G	rs76151804	470	0.00331	29%	CF-causing
c.1000C>T	p.Arg334Trp	R334W	rs121909011	429	0.00302	40%	CF-causing
c.1766+1G>A	No protein name	1898+1G->A	rs121908748	421	0.00296	99%	CF-causing
c.54-5940_273+10250del21kb	p.Ser18ArgfsX16	CFTRdele2,3	not found	417	0.00294	100%	CF-causing
c.1679G>C	p.Arg560Thr	R560T	rs80055610	343	0.00241	98%	CF-causing
c.617T>G	p. Leu206Trp	L206W	rs121908752	333	0.00234	20%	CF-causing
c.2052dupA	p.Gln685ThrfsX4	2184insA	rs121908786	329	0.00232	85%	CF-causing
c.262_263delTT	p. Leu88IlefsX22	394delTT	rs121908769	307	0.00216	97%	CF-causing
c.178G>T	p.Glu60X	E60X	rs77284892	296	0.00208	99%	CF-causing
c.1477C>T	p.Gln493X	Q493X	rs77101217	292	0.00206	98%	CF-causing
c.579+1G>T	No protein name	711+1G->T	rs77188391	274	0.00193	98%	CF-causing
c.2052delA	p. Lys684AsnfsX38	2184delA	rs121908746	255	0.00180	98%	CF-causing
c.200C>T	p.Pro67Leu	P67L	rs368505753	239	0.00168	34%	CF-causing
c.3302T>A	p.Met1101Lys	M1101K	rs36210737	238	0.00168	69%	CF-causing
c.1408A>G	p.Met470Val	M470V	rs213950	235	0.00165	46%	Non CF-causing
c.3276C>A or c.3276C>G	p.Tyr1092X	Y1092X	rs121908761	225	0.00158	98%	CF-causing
c.3196C>T	p.Arg1066Cys	R1066C	rs78194216	220	0.00155	98%	CF-causing
c.1021_1022dupTC	p.Phe342HisfsX28	1154insTC	rs387906360	214	0.00151	99%	CF-causing
c.3773dupT	p. Leu1258PhefsX7	3905insT	rs121908789	210	0.00148	97%	CF-causing
c.1646G>A	p.Ser549Asn	S549N	rs121908755	203	0.00143	84%	CF-causing
c.1040G>A	p.Arg347His	R347H	rs77932196	199	0.00140	24%	CF-causing
c.948delT	p.Phe316LeufsX12	1078delT	rs121908744	184	0.00130	99%	CF-causing
c.1210-33_1210-6GT[12]T[4]	No protein name	5T;TG12	not found	182	0.00128	14%	Varying clinical consequence
c.3472C>T	p.Arg1158X	R1158X	rs79850223	179	0.00126	99%	CF-causing
c.2834C>T	p.Ser945Leu	S945L	rs397508442	167	0.00118	40%	CF-causing
c.1558G>T	p. Val520Phe	V520F	rs77646904	156	0.00110	98%	CF-causing
c.443T>C	p. Ile148Thr	I148T	rs35516286	148	0.00104	88%	Non CF-causing
c.349C>T	p.Arg117Cys	R117C	rs77834169	146	0.00103	24%	CF-causing

DeltaF508

DeltaF508 (ΔF508), full name CFTRΔF508 or F508del-CFTR (rs113993960), is a specific mutation within the CFTR gene involving deletion of three nucleotides spanning codons for amino acid positions 507 and 508 of the CFTR gene on chromosome 7, which ultimately results in the loss of a single codon for the amino acid phenylalanine (F). A person with the CFTRΔF508 mutation will produce an abnormal CFTR protein that lacks this phenylalanine residue and which cannot fold properly. Most of this mutated protein does not escape the endoplasmic reticulum for further processing. The small amounts that reach the plasma membrane are destabilized and the anion channel opens infrequently. Having two copies of this mutation (one inherited from each parent) is by far the most common cause of cystic fibrosis (CF), responsible for nearly two-thirds of mutations worldwide.^[34]

Effects

The CFTR protein is largely expressed in cells of the pancreas, intestinal and respiratory epithelia, and all exocrine glands. When properly folded, it is shuttled to the cell membrane, where it becomes a transmembrane protein that forms aqueous channels allowing the flow of chloride and bicarbonate ions out of cells; it also simultaneously inhibits the uptake of sodium ions by another channel protein. Both of these functions help to maintain an ion gradient that causes osmosis to draw water out of the cells.^[35] The ΔF508 mutation leads to the misfolding of CFTR and its eventual degradation in the ER. In organisms with two complements of the mutation, the protein is almost entirely absent from the cell membrane, and these critical ion transport functions are not performed.^[36]

Having a homozygous pair of genes with the ΔF508 mutation prevents the CFTR protein from assuming its normal position in the cell membrane. This causes increased water retention in cells, corresponding dehydration of the extracellular space, and an associated cascade of effects on various parts of the body. These effects include: thicker mucous membranes in the epithelia of afflicted organs; obstruction of narrow respiratory airways as a result of thicker mucus and inhibition of the free movement of muco cilia; congenital absence of the vas deferens due to increased mucus thickness during fetal development; pancreatic insufficiency due to blockage of the pancreatic duct with mucus; and increased risk of respiratory infection due to build-up of thick, nutrient-rich mucus where bacteria thrive. These are the symptoms of cystic fibrosis, a genetic disorder; however, ΔF508 is not the only mutation that causes this disorder.^[37]

Being a heterozygous carrier (having a single copy of ΔF508) results in decreased water loss during diarrhea because malfunctioning or absent CFTR proteins cannot maintain stable ion gradients across cell membranes. Typical nucleotide-binding-up of both Cl⁻ and Na⁺ ions inside affected cells, creating a hypotonic solution outside the cells and causing water to diffuse into the cells by osmosis. Several studies indicate that heterozygous carriers are at increased risk for various symptoms. For example, it has been shown that heterozygosity for cystic fibrosis is associated with increased airway reactivity, and heterozygotes may be at risk for poor pulmonary function. Heterozygotes with wheeze have been shown to be at higher risk for poor pulmonary function or development and progression of chronic obstructive lung disease. One gene for cystic fibrosis is sufficient to produce mild lung abnormalities even in the absence of infection.^[38]

Mechanism

The CFTR gene is located on the long arm of chromosome 7, at position q31.2, and ultimately codes for a sequence of 1,480 amino acids. Normally, the three DNA base pairs A-T-C (paired with T-A-G on the opposite strand) at the gene's 507th position form the template for the mRNA codon A-U-C for isoleucine, while the three DNA base pairs T-T-T (paired with A-A-A) at the adjacent 508th position form the template for the codon U-U-U for phenylalanine.^[39] The ΔF508 mutation is a deletion of the C-G pair from position 507 along with the first two T-A pairs from position 508, leaving the DNA sequence A-T-T (paired with T-A-A) at position 507, which is transcribed into the mRNA codon A-U-U. Since A-U-U also codes for isoleucine, position 507's amino acid does not change, and the mutation's net effect is equivalent to a deletion ("Δ") of the sequence resulting in the codon for phenylalanine at position 508.^[40]

Prevalence

ΔF508 is present on at least one copy of chromosome 7 in approximately one in 30 Caucasians. Presence of the mutation on both copies causes the autosomal recessive disease cystic fibrosis. Scientists have estimated that the original mutation occurred over 52,000 years ago in Northern Europe though cystic fibrosis patients of other ethnicities are also known to harbor the mutation. The young allele age may be a consequence of past selection. One hypothesis as to why the otherwise detrimental mutation has been maintained by natural selection is that a single copy may present a positive effect by reducing water loss during cholera, though the introduction of pathogenic Vibrio cholerae into Europe did not occur until the late 18th century.^[41] Another theory posits that CF carriers (heterozygotes for ΔF508) are more resistant to typhoid fever, since CFTR has been shown to act as a receptor for Salmonella typhi bacteria to enter intestinal epithelial cells.^[42]

Cystic fibrosis ΔF508 heterozygotes may be overrepresented among individuals with asthma and may have poorer lung function than non-carriers.^[43][44] Carriers of a single CF mutation have a higher prevalence of chronic rhinosinusitis than the general population.^[45] Approximately 50% of cystic fibrosis cases in Europe are due to homozygous ΔF508 mutations (this varies widely by region),^[46] while the allele frequency of ΔF508 is about 70%.^[47] The remaining cases are caused by over 1,500 other mutations, including R117H, 1717-1G>A, and 2789+56G>A. These mutations, when combined with each other or even a single copy of ΔF508, may cause CF symptoms. The genotype is not strongly correlated with severity of the CF, though specific symptoms have been linked to certain mutations.

Structure

The Overall Structure of Human CFTR in the Dephosphorylated, ATP-Free Conformation. Domains are labeled. Made from PDB 5UAK ^[48]

The CFTR gene is approximately 189 kb in length, with 27 exons and 26 introns.^[49] CFTR is a glycoprotein and is found on the surface of many epithelial cells in the body.^[50] CFTR consists of five domains, which include two transmembrane or membrane-spanning domains, two nucleotide-binding domains and a regulatory domain.^[51] The transmembrane domains are each connected to a nucleotide binding domain (NBD) in the cytoplasm. The first NBD is connected to the second transmembrane domain by a regulatory "R" domain that is a unique feature of CFTR, not present in other ABC transporters which carries 19 predicted sites for protein kinase A(PKA). Six of these have been reported to be phosphorylated in vivo.^[52] The ion channel only opens when its R-domain has been phosphorylated by PKA and ATP is bound at the NBDs. Phosphorylation displaces the disordered R domain from positions preventing NBD dimerization and opening.^[53][54] The amino-terminus is part of the lasso motif which anchors into the cell membrane.^[52] The carboxyl terminal of the protein is anchored to the cytoskeleton by a PDZ-interacting domain.^[55]

Location and function

The CFTR protein is a channel protein that controls the flow of H₂O and Cl⁻ ions in and out of cells inside the lungs. When the CFTR protein is working correctly, as shown in Panel 1, ions freely flow in and out of the cells. However, when the CFTR protein is malfunctioning as in Panel 2, these ions cannot flow out of the cell due to blocked CFTR channels. This occurs in cystic fibrosis, characterized by the buildup of thick mucus in the lungs.

The CFTR gene is made up of 27 exons that encode its gene makeup and is found on the long (q) arm of chromosome 7 at locus 31.2. Exons are DNA fragments that provide the code for a protein structure.^[50] CFTR functions as phosphorylation and ATP-gated anion channel, increasing the conductance for certain anions (e.g. Cl⁻) to flow down their electrochemical gradient. ATP-driven conformational changes in CFTR open and close a gate to allow the transmembrane flow of anions down their electrochemical gradient.^[5] This in contrast to other ABC proteins, in which ATP-driven conformational changes fuel uphill substrate transport across cellular membranes. Essentially, CFTR is an ion channel that evolved as a 'broken' ABC transporter that leaks when in the open conformation.

CFTRs consist of five domains including two trans-membrane domains, each linked to a nucleotide-binding domain. CFTR also contains another domain called the regulatory domain. Other members of the ABC transporter superfamily are involved in the uptake of nutrients in prokaryotes, or in the export of a variety of substrates in eukaryotes. ABC transporters have evolved to transduce the free energy of ATP hydrolysis to the uphill movement of substrates across the cell membrane. They have two main conformations, one where the cargo binding site is facing the cytosol or inward facing (ATP free), and one where it is outward facing (ATP bound). ATP binds to each nucleotide-binding domain, which results in the subsequent NBD dimerization, leading to the rearrangement of the transmembrane helices. This changes the accessibility of the cargo binding site from an inward-facing position to an outward facing one. ATP binding, and the hydrolysis that follows, drives the alternative exposure of the cargo binding site, ensuring a unidirectional transport of cargo against an electrochemical gradient. In CFTR, alternating between an inward-facing conformation to an outward-facing one results in channel gating. In particular, NBD dimerization (favored by ATP binding) is coupled to transition to an outward-facing conformation in which an open transmembrane pathway for anions is formed.^[56] Subsequent hydrolysis (at the canonical active site, site 2, including Walker motifs of NBD2) destabilizes the NBD dimer and favors return to the inward-facing conformation, in which the anion permeation pathway is closed off.^[5]

Clinical implications

Different CFTR mutations can lead to varying degrees of cystic fibrosis severity. Common symptoms include chronic lung infections, pancreatic insufficiency, and high sweat chloride levels. Mutation-specific therapies, such as CFTR modulators, have been developed to address these specific genetic defects.^[57]

Interactions

Cystic fibrosis transmembrane conductance regulator has been shown to interact with:

• DNAJC5,^[58]
• GOPC,^[59][60]
• PDZK1,^[60][61]
• PRKCE,^[62]
• SLC4A8,^[63]
• SNAP23,^[64]
• SLC9A3R1,^{[55][63][65][66][67][68]}
• SLC9A3R2,^[69] and
• STX1A,^[64][70]

It is inhibited by the anti-diarrhoea drug crofelemer.

Related conditions

• Congenital bilateral absence of vas deferens: Males with congenital bilateral absence of the vas deferens most often have a mild mutation (a change that allows partial function of the gene) in one copy of the CFTR gene and a cystic fibrosis-causing mutation in the other copy of CFTR.
• Cystic fibrosis: More than 1,800 mutations in the CFTR gene have been found^[71] but the majority of these have not been associated with cystic fibrosis.^[72] Most of these mutations either substitute one amino acid (a building block of proteins) for another amino acid in the CFTR protein or delete a small amount of DNA in the CFTR gene. The most common mutation, called ΔF508, is a deletion (Δ) of one amino acid (phenylalanine) at position 508 in the CFTR protein. This altered protein never reaches the cell membrane because it is degraded shortly after it is made. All disease-causing mutations in the CFTR gene prevent the channel from functioning properly, leading to a blockage of the movement of salt and water into and out of cells. As a result of this blockage, cells that line the passageways of the lungs, pancreas, and other organs produce abnormally thick, sticky mucus. This mucus obstructs the airways and glands, causing the characteristic signs and symptoms of cystic fibrosis. In addition, only thin mucus can be removed by cilia; thick mucus cannot, so it traps bacteria that give rise to chronic infections.
• Cholera: ADP-ribosylation caused by cholera toxin results in increased production of cyclic AMP which in turn opens the CFTR channel which leads to Over secretion of Cl⁻. Na⁺ and H₂O follow Cl⁻ into the small intestine, resulting in dehydration and loss of electrolytes.^[73]

Drug target

CFTR has been a drug target in efforts to find treatments for related conditions. Ivacaftor (brand name Kalydeco, developed as VX-770) is a medication approved by the FDA in 2012, for people with cystic fibrosis who have specific CFTR mutations.^[74][75] Ivacaftor was developed by Vertex Pharmaceuticals in conjunction with the Cystic Fibrosis Foundation and is the first medication that treats the underlying cause rather than the symptoms of the disease.^[76][77] and "a wonder drug"^[78]

The combination vanzacaftor/tezacaftor/deutivacaftor (brand name Alyftrek) was approved for medical use in the United States in December 2024.^[79]

References

1. GRCh38: Ensembl release 89: ENSG00000001626 – Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000041301 – Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Csanády L, Vergani P, Gadsby DC (January 2019). "Structure, Gating, and Regulation of the CFTR Anion Channel". Physiological Reviews. 99 (1): 707–738. doi:10.1152/physrev.00007.2018. PMID 30516439.
6. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al. (September 1989). "Identification of the cystic fibrosis gene: chromosome walking and jumping". Science. 245 (4922): 1059–1065. Bibcode:1989Sci...245.1059R. doi:10.1126/science.2772657. PMID 2772657.
7. "Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene | The Embryo Project Encyclopedia". embryo.asu.edu. Retrieved 26 September 2022.
8. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. (September 1989). "Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA". Science. 245 (4922): 1066–1073. Bibcode:1989Sci...245.1066R. doi:10.1126/science.2475911. PMID 2475911. S2CID 84566748.
9. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. (September 1989). "Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA". Science. 245 (4922): 1066–1073. doi:10.1016/0168-9525(89)90155-8. PMID 2475911.
10. Marcorelles P, Gillet D, Friocourt G, Ledé F, Samaison L, Huguen G, et al. (March 2012). "Cystic fibrosis transmembrane conductance regulator protein expression in the male excretory duct system during development". Human Pathology. 43 (3): 390–397. doi:10.1016/j.humpath.2011.04.031. PMID 21840567.
11. Bregman T, Fride E (June 2011). "Treatment with tetrahydrocannabinol (THC) prevents infertility in male cystic fibrosis mice". Journal of Basic and Clinical Physiology and Pharmacology. 22 (1–2): 29–32. doi:10.1515/jbcpp.2011.004. PMID 22865360. S2CID 19335113.
12. Enuka Y, Hanukoglu I, Edelheit O, Vaknine H, Hanukoglu A (March 2012). "Epithelial sodium channels (ENaC) are uniformly distributed on motile cilia in the oviduct and the respiratory airways". Histochemistry and Cell Biology. 137 (3): 339–353. doi:10.1007/s00418-011-0904-1. PMID 22207244. S2CID 15178940.
13. Sharma S, Hanukoglu A, Hanukoglu I (April 2018). "Localization of epithelial sodium channel (ENaC) and CFTR in the germinal epithelium of the testis, Sertoli cells, and spermatozoa". Journal of Molecular Histology. 49 (2): 195–208. doi:10.1007/s10735-018-9759-2. PMID 29453757. S2CID 3761720.
14. Sharma S, Hanukoglu I (April 2019). "Mapping the sites of localization of epithelial sodium channel (ENaC) and CFTR in segments of the mammalian epididymis". Journal of Molecular Histology. 50 (2): 141–154. doi:10.1007/s10735-019-09813-3. PMID 30659401. S2CID 58026884.
15. Sharma S, Kumaran GK, Hanukoglu I (February 2020). "High-resolution imaging of the actin cytoskeleton and epithelial sodium channel, CFTR, and aquaporin-9 localization in the vas deferens". Mol Reprod Dev. 87 (2): 305–319. doi:10.1002/mrd.23317. PMID 31950584.
16. "CF Study Finds New Cells Called Ionocytes Carrying High levels of CFTR Gene". Cystic Fibrosis News Today. 3 August 2018.
17. Montoro DT, Haber AL, Biton M, Vinarsky V, Lin B, Birket SE, et al. (August 2018). "A revised airway epithelial hierarchy includes CFTR-expressing ionocytes". Nature. 560 (7718): 319–324. Bibcode:2018Natur.560..319M. doi:10.1038/s41586-018-0393-7. PMC 6295155. PMID 30069044.
18. Plasschaert LW, Žilionis R, Choo-Wing R, Savova V, Knehr J, Roma G, et al. (August 2018). "A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte". Nature. 560 (7718): 377–381. Bibcode:2018Natur.560..377P. doi:10.1038/s41586-018-0394-6. PMC 6108322. PMID 30069046.
19. Hanukoglu I, Boggula VR, Vaknine H, Sharma S, Kleyman T, Hanukoglu A (June 2017). "Expression of epithelial sodium channel (ENaC) and CFTR in the human epidermis and epidermal appendages". Histochemistry and Cell Biology. 147 (6): 733–748. doi:10.1007/s00418-016-1535-3. PMID 28130590. S2CID 8504408.
20. Moskwa P, Lorentzen D, Excoffon KJ, Zabner J, McCray PB, Nauseef WM, et al. (January 2007). "A novel host defense system of airways is defective in cystic fibrosis". American Journal of Respiratory and Critical Care Medicine. 175 (2): 174–183. doi:10.1164/rccm.200607-1029OC. PMC 2720149. PMID 17082494.
21. Xu Y, Szép S, Lu Z (December 2009). "The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases". Proceedings of the National Academy of Sciences of the United States of America. 106 (48): 20515–20519. Bibcode:2009PNAS..10620515X. doi:10.1073/pnas.0911412106. PMC 2777967. PMID 19918082.
22. Yonei Y, Tanaka M, Ozawa Y, Miyazaki K, Tsukada N, Inada S, et al. (April 1992). "Primary hepatocellular carcinoma with severe hypoglycemia: involvement of insulin-like growth factors". Liver. 12 (2): 90–93. doi:10.1111/j.1600-0676.1992.tb00563.x. PMID 1320177.
23. "OrthoMaM phylogenetic marker: CFTR coding sequence". Archived from the original on 2 March 2016. Retrieved 12 March 2010.
24. Davies R, Conroy SJ, Davies WL, Potter IC, Trezise AE (19–23 June 2005). "Evolution and Regulation of the Cystic Fibrosis Gene" (conference paper). Molecular Biology and Evolution (MBE05) Conference. Retrieved 28 July 2014.
25. Welsh MJ, Smith AE (July 1993). "Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis". Cell. 73 (7): 1251–1254. doi:10.1016/0092-8674(93)90353-r. PMID 7686820.
26. "Genetics and CF". The Cystic Fibrosis Center at Stanford (in Samoan). Retrieved 23 October 2022.
27. Prasad AB, Allard MW, Green ED (September 2008). "Confirming the phylogeny of mammals by use of large comparative sequence data sets". Molecular Biology and Evolution. 25 (9): 1795–1808. doi:10.1093/molbev/msn104. PMC 2515873. PMID 18453548.
28. "The Clinical and Functional TRanslation of CFTR (CFTR2): CFTR2 Variant List History". US CF Foundation, Johns Hopkins University, Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto. Retrieved 2 August 2017.^{[permanent dead link‍]}
29. Guimbellot J, Sharma J, Rowe SM (November 2017). "Toward inclusive therapy with CFTR modulators: Progress and challenges". Pediatric Pulmonology. 52 (S48): S4 – S14. doi:10.1002/ppul.23773. PMC 6208153. PMID 28881097.
30. Shekdar K, Langer J, Venkatachalan S, Schmid L, Anobile J, Shah P, et al. (May 2021). "Cell engineering method using fluorogenic oligonucleotide signaling probes and flow cytometry". Biotechnology Letters. 43 (5): 949–958. doi:10.1007/s10529-021-03101-5. PMC 7937778. PMID 33683511.
31. Rowe SM, Miller S, Sorscher EJ (May 2005). "Cystic fibrosis". The New England Journal of Medicine. 352 (19): 1992–2001. doi:10.1056/NEJMra043184. PMID 15888700.
32. Kavic SM, Frehm EJ, Segal AS (1999). "Case studies in cholera: lessons in medical history and science". The Yale Journal of Biology and Medicine. 72 (6): 393–408. PMC 2579035. PMID 11138935.
33. "CFTR2". Retrieved 8 July 2021.
34. Bobadilla JL, Macek M, Fine JP, Farrell PM (June 2002). "Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening". Human Mutation. 19 (6): 575–606. doi:10.1002/humu.10041. PMID 12007216.
35. Verkman AS, Song Y, Thiagarajah JR (January 2003). "Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease". American Journal of Physiology. Cell Physiology. 284 (1): C2-15. doi:10.1152/ajpcell.00417.2002. PMID 12475759.
36. "Cystic Fibrosis Research Directions". National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).^{[dead link‍]}
37. Boyle MP, De Boeck K (April 2013). "A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect". The Lancet. Respiratory Medicine. 1 (2): 158–163. doi:10.1016/s2213-2600(12)70057-7. PMID 24429096.
38. Maurya N, Awasthi S, Dixit P (April 2012). "Association of CFTR gene mutation with bronchial asthma" (PDF). The Indian Journal of Medical Research. 135 (4): 469–478. PMC 3385229. PMID 22664493. Archived from the original (PDF) on 12 March 2020. Retrieved 16 March 2019.
39. CCDS Report for Consensus CDS: Report for CCDS5773.1 (current version) NCBI
40. Bartoszewski RA, Jablonsky M, Bartoszewska S, Stevenson L, Dai Q, Kappes J, et al. (September 2010). "A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein". The Journal of Biological Chemistry. 285 (37): 28741–28748. doi:10.1074/jbc.M110.154575. PMC 2937902. PMID 20628052.
41. "Re: Is there a connection between cystic fibrosis and cholera?".
42. Pier GB, Grout M, Zaidi T, Meluleni G, Mueschenborn SS, Banting G, et al. (May 1998). "Salmonella typhi uses CFTR to enter intestinal epithelial cells". Nature. 393 (6680): 79–82. Bibcode:1998Natur.393...79P. doi:10.1038/30006. PMID 9590693. S2CID 5894247.
43. Dahl M, Nordestgaard BG, Lange P, Tybjaerg-Hansen A (May 2001). "Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion". The Journal of Allergy and Clinical Immunology. 107 (5): 818–823. doi:10.1067/mai.2001.114117. PMID 11344348.
44. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG (June 1998). "DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma". Lancet. 351 (9120): 1911–1913. doi:10.1016/s0140-6736(97)11419-2. PMID 9654257. S2CID 22970136.
45. Wang X, Kim J, McWilliams R, Cutting GR (March 2005). "Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation". Archives of Otolaryngology–Head & Neck Surgery. 131 (3): 237–240. doi:10.1001/archotol.131.3.237. PMID 15781764.
46. ECFS Annual Report: What It Means to the UK Archived 1 May 2018 at the Wayback Machine Cystic Fibrosis Trust
47. Morral N, Bertranpetit J, Estivill X, Nunes V, Casals T, Giménez J, et al. (June 1994). "The origin of the major cystic fibrosis mutation (delta F508) in European populations". Nature Genetics. 7 (2): 169–175. doi:10.1038/ng0694-169. PMID 7920636. S2CID 38005421.
48. "5UAK: Dephosphorylated, ATP-free human cystic fibrosis transmembrane conductance regulator (CFTR)". RCSB Protein Data Bank. 19 December 2016. Retrieved 24 December 2024.
49. Cystic Fibrosis Mutation Database. "Genomic DNA sequence". Archived from the original on 22 August 2016. Retrieved 6 April 2013.
50. "CFTR". Johns Hopkins Cystic Fibrosis Center. Retrieved 9 October 2022.
51. Sheppard DN, Welsh MJ (January 1999). "Structure and function of the CFTR chloride channel". Physiological Reviews. 79 (1 Suppl): S23 – S45. doi:10.1152/physrev.1999.79.1.S23. PMID 9922375.
52. Zhang Z, Liu F, Chen J (December 2018). "Molecular structure of the ATP-bound, phosphorylated human CFTR". Proceedings of the National Academy of Sciences of the United States of America. 115 (50): 12757–12762. Bibcode:2018PNAS..11512757Z. doi:10.1073/pnas.1815287115. PMC 6294961. PMID 30459277.
53. Zhang Z, Liu F, Chen J (July 2017). "Conformational Changes of CFTR upon Phosphorylation and ATP Binding". Cell. 170 (3): 483–491.e8. doi:10.1016/j.cell.2017.06.041. PMID 28735752. S2CID 5361509.
54. Sheppard DN, Welsh MJ (January 1999). "Structure and function of the CFTR chloride channel". Physiological Reviews. 79 (1 Suppl): S23 – S45. doi:10.1152/physrev.1999.79.1.S23. PMID 9922375.
55. Short DB, Trotter KW, Reczek D, Kreda SM, Bretscher A, Boucher RC, et al. (July 1998). "An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton". The Journal of Biological Chemistry. 273 (31): 19797–19801. doi:10.1074/jbc.273.31.19797. PMID 9677412.
56. Vergani P, Lockless SW, Nairn AC, Gadsby DC (2005). "CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains". Nature. 433 (7028): 876–80. Bibcode:2005Natur.433..876V. doi:10.1038/nature03313. PMC 2756053. PMID 15729345. S2CID 4383918.
57. Boyle MP, De Boeck K (April 2013). "A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect". The Lancet. Respiratory Medicine. 1 (2): 158–163. doi:10.1016/s2213-2600(12)70057-7. PMID 24429096.
58. Zhang H, Peters KW, Sun F, Marino CR, Lang J, Burgoyne RD, et al. (August 2002). "Cysteine string protein interacts with and modulates the maturation of the cystic fibrosis transmembrane conductance regulator". The Journal of Biological Chemistry. 277 (32): 28948–28958. doi:10.1074/jbc.M111706200. PMID 12039948.
59. Cheng J, Moyer BD, Milewski M, Loffing J, Ikeda M, Mickle JE, et al. (February 2002). "A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression". The Journal of Biological Chemistry. 277 (5): 3520–3529. doi:10.1074/jbc.M110177200. PMID 11707463.
60. Gentzsch M, Cui L, Mengos A, Chang XB, Chen JH, Riordan JR (February 2003). "The PDZ-binding chloride channel ClC-3B localizes to the Golgi and associates with cystic fibrosis transmembrane conductance regulator-interacting PDZ proteins". The Journal of Biological Chemistry. 278 (8): 6440–6449. doi:10.1074/jbc.M211050200. PMID 12471024.
61. Wang S, Yue H, Derin RB, Guggino WB, Li M (September 2000). "Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity". Cell. 103 (1): 169–179. doi:10.1016/S0092-8674(00)00096-9. PMID 11051556. S2CID 16697781.
62. Liedtke CM, Yun CH, Kyle N, Wang D (June 2002). "Protein kinase C epsilon-dependent regulation of cystic fibrosis transmembrane regulator involves binding to a receptor for activated C kinase (RACK1) and RACK1 binding to Na+/H+ exchange regulatory factor". The Journal of Biological Chemistry. 277 (25): 22925–22933. doi:10.1074/jbc.M201917200. PMID 11956211.
63. Park M, Ko SB, Choi JY, Muallem G, Thomas PJ, Pushkin A, et al. (December 2002). "The cystic fibrosis transmembrane conductance regulator interacts with and regulates the activity of the HCO3- salvage transporter human Na+-HCO3- cotransport isoform 3". The Journal of Biological Chemistry. 277 (52): 50503–50509. doi:10.1074/jbc.M201862200. PMID 12403779.
64. Cormet-Boyaka E, Di A, Chang SY, Naren AP, Tousson A, Nelson DJ, et al. (September 2002). "CFTR chloride channels are regulated by a SNAP-23/syntaxin 1A complex". Proceedings of the National Academy of Sciences of the United States of America. 99 (19): 12477–12482. Bibcode:2002PNAS...9912477C. doi:10.1073/pnas.192203899. PMC 129470. PMID 12209004.
65. Hegedüs T, Sessler T, Scott R, Thelin W, Bakos E, Váradi A, et al. (March 2003). "C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins". Biochemical and Biophysical Research Communications. 302 (3): 454–461. doi:10.1016/S0006-291X(03)00196-7. PMID 12615054.
66. Wang S, Raab RW, Schatz PJ, Guggino WB, Li M (May 1998). "Peptide binding consensus of the NHE-RF-PDZ1 domain matches the C-terminal sequence of cystic fibrosis transmembrane conductance regulator (CFTR)". FEBS Letters. 427 (1): 103–108. Bibcode:1998FEBSL.427..103W. doi:10.1016/S0014-5793(98)00402-5. PMID 9613608. S2CID 20803242.
67. Moyer BD, Duhaime M, Shaw C, Denton J, Reynolds D, Karlson KH, et al. (September 2000). "The PDZ-interacting domain of cystic fibrosis transmembrane conductance regulator is required for functional expression in the apical plasma membrane". The Journal of Biological Chemistry. 275 (35): 27069–27074. doi:10.1074/jbc.M004951200. PMID 10852925.
68. Hall RA, Ostedgaard LS, Premont RT, Blitzer JT, Rahman N, Welsh MJ, et al. (July 1998). "A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins". Proceedings of the National Academy of Sciences of the United States of America. 95 (15): 8496–8501. Bibcode:1998PNAS...95.8496H. doi:10.1073/pnas.95.15.8496. PMC 21104. PMID 9671706.
69. Sun F, Hug MJ, Lewarchik CM, Yun CH, Bradbury NA, Frizzell RA (September 2000). "E3KARP mediates the association of ezrin and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells". The Journal of Biological Chemistry. 275 (38): 29539–29546. doi:10.1074/jbc.M004961200. PMID 10893422.
70. Naren AP, Nelson DJ, Xie W, Jovov B, Pevsner J, Bennett MK, et al. (November 1997). "Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms". Nature. 390 (6657): 302–305. Bibcode:1997Natur.390..302N. doi:10.1038/36882. PMID 9384384. S2CID 4395005.
71. Egan ME (March 2016). "Genetics of Cystic Fibrosis: Clinical Implications". Clinics in Chest Medicine. 37 (1): 9–16. doi:10.1016/j.ccm.2015.11.002. PMID 26857764.
72. De Boeck K, Amaral MD (August 2016). "Progress in therapies for cystic fibrosis". The Lancet. Respiratory Medicine. 4 (8): 662–674. doi:10.1016/S2213-2600(16)00023-0. PMID 27053340.
73. Thiagarajah JR, Verkman AS (September 2012). "CFTR inhibitors for treating diarrheal disease". Clinical Pharmacology and Therapeutics. 92 (3): 287–290. doi:10.1038/clpt.2012.114. PMC 3643514. PMID 22850599.
74. Jones AM, Helm JM (October 2009). "Emerging treatments in cystic fibrosis". Drugs. 69 (14): 1903–1910. doi:10.2165/11318500-000000000-00000. PMID 19747007. S2CID 23344660.
75. McPhail GL, Clancy JP (April 2013). "Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis". Drugs of Today. 49 (4): 253–260. doi:10.1358/dot.2013.49.4.1940984. PMID 23616952.
76. "Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation" (Press release). Cystic Fibrosis Foundation. 23 February 2011.
77. Herper M (27 December 2012). "The Most Important New Drug Of 2012". Forbes.
78. Nocera J (18 July 2014). "The $300,000 Drug". The New York Times.
79. "Vertex Announces US FDA Approval of Alyftrek, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis" (Press release). Vertex. 20 December 2024. Retrieved 24 December 2024 – via Business Wire.

Further reading

• Boyle MP (2000). "Unique presentations and chronic complications in adult cystic fibrosis: do they teach us anything about CFTR?". Respiratory Research. 1 (3): 133–135. doi:10.1186/rr23. PMC 59552. PMID 11667976.
• Bradbury NA (2001). "cAMP signaling cascades and CFTR: is there more to learn?". Pflügers Archiv. 443 (Suppl 1): S85 – S91. doi:10.1007/s004240100651. PMID 11845310. S2CID 19373036.
• Cohn JA, Mitchell RM, Jowell PS (March 2005). "The impact of cystic fibrosis and PSTI/SPINK1 gene mutations on susceptibility to chronic pancreatitis". Clinics in Laboratory Medicine. 25 (1): 79–100. doi:10.1016/j.cll.2004.12.007. PMID 15749233.
• Cohn JA, Noone PG, Jowell PS (September 2002). "Idiopathic pancreatitis related to CFTR: complex inheritance and identification of a modifier gene". Journal of Investigative Medicine. 50 (5): 247S – 255S. doi:10.1136/jim-50-suppl5-01. PMID 12227654. S2CID 34017638.
• Cuppens H, Cassiman JJ (October 2004). "CFTR mutations and polymorphisms in male infertility". International Journal of Andrology. 27 (5): 251–256. doi:10.1111/j.1365-2605.2004.00485.x. PMID 15379964.
• Dahan D, Evagelidis A, Hanrahan JW, Hinkson DA, Jia Y, Luo J, et al. (2001). "Regulation of the CFTR channel by phosphorylation". Pflügers Archiv. 443 (Suppl 1): S92 – S96. doi:10.1007/s004240100652. PMID 11845311. S2CID 8144727.
• Devidas S, Guggino WB (October 1997). "CFTR: domains, structure, and function". Journal of Bioenergetics and Biomembranes. 29 (5): 443–451. doi:10.1023/A:1022430906284. PMID 9511929. S2CID 6000695.
• Drumm ML, Collins FS (1993). "Molecular biology of cystic fibrosis". Molecular Genetic Medicine. 3: 33–68. doi:10.1016/b978-0-12-462003-2.50006-7. ISBN 9780124620032. PMID 7693108.
• Greger R, Schreiber R, Mall M, Wissner A, Hopf A, Briel M, et al. (2001). "Cystic fibrosis and CFTR". Pflügers Archiv. 443 (Suppl 1): S3 – S7. doi:10.1007/s004240100635. PMID 11845294. S2CID 8057614.
• Kandula L, Whitcomb DC, Lowe ME (June 2006). "Genetic issues in pediatric pancreatitis". Current Gastroenterology Reports. 8 (3): 248–253. doi:10.1007/s11894-006-0083-8. PMID 16764792. S2CID 23606613.
• Kerem B, Kerem E (1996). "The molecular basis for disease variability in cystic fibrosis". European Journal of Human Genetics. 4 (2): 65–73. doi:10.1159/000472174 (inactive 22 December 2024). PMID 8744024. S2CID 41476164.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
• Kulczycki LL, Kostuch M, Bellanti JA (January 2003). "A clinical perspective of cystic fibrosis and new genetic findings: relationship of CFTR mutations to genotype-phenotype manifestations". American Journal of Medical Genetics. Part A. 116A (3): 262–267. doi:10.1002/ajmg.a.10886. PMID 12503104. S2CID 9245855.
• Marcet B, Boeynaems JM (December 2006). "Relationships between cystic fibrosis transmembrane conductance regulator, extracellular nucleotides and cystic fibrosis". Pharmacology & Therapeutics. 112 (3): 719–732. doi:10.1016/j.pharmthera.2006.05.010. PMID 16828872.
• McIntosh I, Cutting GR (July 1992). "Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis". FASEB Journal. 6 (10): 2775–2782. doi:10.1096/fasebj.6.10.1378801. PMID 1378801. S2CID 24932803.
• Nagel G (December 1999). "Differential function of the two nucleotide binding domains on cystic fibrosis transmembrane conductance regulator". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1461 (2): 263–274. doi:10.1016/S0005-2736(99)00162-5. PMID 10581360.
• Schwartz M (February 2003). "[Cystic fibrosis transmembrane conductance regulator (CFTR) gene: mutations and clinical phenotypes]". Ugeskrift for Laeger. 165 (9): 912–916. PMID 12661515.
• Southern KW, Peckham D (2004). "Establishing a diagnosis of cystic fibrosis". Chronic Respiratory Disease. 1 (4): 205–210. doi:10.1191/1479972304cd044rs. PMID 16281647.
• Tsui LC (1992). "Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium". Human Mutation. 1 (3): 197–203. doi:10.1002/humu.1380010304. PMID 1284534. S2CID 35904538.
• Vankeerberghen A, Cuppens H, Cassiman JJ (March 2002). "The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions". Journal of Cystic Fibrosis. 1 (1): 13–29. doi:10.1016/S1569-1993(01)00003-0. PMID 15463806.
• Wilschanski M, Durie PR (August 2007). "Patterns of GI disease in adulthood associated with mutations in the CFTR gene". Gut. 56 (8): 1153–1163. doi:10.1136/gut.2004.062786. PMC 1955522. PMID 17446304.
• Wong LJ, Alper OM, Wang BT, Lee MH, Lo SY (July 2003). "Two novel null mutations in a Taiwanese cystic fibrosis patient and a survey of East Asian CFTR mutations". American Journal of Medical Genetics. Part A. 120A (2): 296–298. doi:10.1002/ajmg.a.20039. PMID 12833420. S2CID 41060230.
• Savant A, Lyman B, Bojanowski C, Upadia J (August 2024). "Cystic Fibrosis". University of Washington, Seattle. PMID 20301428.

External links

• Overview of all the structural information available in the PDB for UniProt: P13569 (Human Cystic fibrosis transmembrane conductance regulator) at the PDBe-KB.
• Overview of all the structural information available in the PDB for UniProt: P26361 (Mouse Cystic fibrosis transmembrane conductance regulator) at the PDBe-KB.